No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 2.5x · 10Y median 3.9x · 13th percentile · as of Sep 4, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Hims & Hers Health, Inc. (HIMS) stock was $27.98 as of Sep 8, 2026, 3:15 PM EDT, up 0.96% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -42.4% · 3-year avg +59.1%/yr · 5-year avg +27.5%/yr
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care.
Medical - Care Facilities · San Francisco, CA
How HIMS’s revenue breaks down across its reported segments in the latest reported fiscal year.
Next Earnings Date
Nov 9, 2026
62 days away
EPS Estimate
0.09
Revenue Est.
$890.88M
Last Quarter Results
EPS
$-0.37
vs Estimate
$-0.05
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1HIMS | $6.24B | $27.98 | +0.96% | -42.42% | +27.53% | N/A | N/A |
| 2CHE | $6.84B | $523.42 | +0.69% | +13.70% | +2.05% | +14.66% | vs HIMS |
| 3SRRK | $6.85B | $57.19 | +3.36% | +70.62% | +8.73% | N/A | vs HIMS |
| 4MMSI | $5.24B | $87.77 | -2.04% | -2.77% | +4.18% | +13.84% | vs HIMS |
| 5DOCS | $4.58B | $24.48 | -7.12% | -61.57% | -23.28% | N/A | vs HIMS |
| 6OSCR | $8.50B | $32.77 | +1.61% | +75.53% | +12.10% | N/A | vs HIMS |
N/A
$753.21M
vs Estimate
$698.90M
Consensus Rating
Based on 13 analysts
Average Price Target
$31.23
+11.6% upside
Low
$23.00
Current
$27.98
High
$42.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.01 | $0.06 | $0.13 | 7 |
| Quarter ending Dec 2026 | $0.06 | $0.12 | $0.21 | 6 |
| Quarter ending Mar 2027 | $-0.02 | $-0.01 | $-0.01 | 2 |
| Quarter ending Jun 2027 | $0.04 | $0.04 | $0.05 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.03 | $-0.58 | $-0.13 | 7 |
| FY 2027 | $0.23 | $0.30 | $0.38 | 8 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $888.59M | $892.84M | $899.91M | 8 |
| Quarter ending Dec 2026 | $857.43M | $952.90M | $1.07B | 8 |
| Quarter ending Mar 2027 | $844.77M | $895.45M | $965.18M | 4 |
| Quarter ending Jun 2027 | $890.27M | $943.69M | $1.02B | 5 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $3.14B | $3.21B | $3.30B | 10 |
| FY 2027 | $3.81B | $4.04B | $4.26B | 11 |
